Please ensure Javascript is enabled for purposes of website accessibility Cir.No.129 of 2025 – Regarding Short-Acting Beta 2 Agonists (SABA) (salbutamol and terbutaline) reminder of the risks from overuse in asthma and to be aware of changes in the SABA prescribing guidelines. Cir.No.129 of 2025 – Regarding Short-Acting Beta 2 Agonists (SABA) (salbutamol and terbutaline) reminder of the risks from overuse in asthma and to be aware of changes in the SABA prescribing guidelines.

Cir.No.129 of 2025 – Regarding Short-Acting Beta 2 Agonists (SABA) (salbutamol and terbutaline) reminder of the risks from overuse in asthma and to be aware of changes in the SABA prescribing guidelines.

Content Details
Pharmacovigilance and drug information Department News and Safety Alerts
Cir.No.129 of 2025 – Regarding Short-Acting Beta 2 Agonists (SABA) (salbutamol and terbutaline) reminder of the risks from overuse in asthma and to be aware of changes in the SABA prescribing guidelines.
24/06/2025

Cir.No.129 of 2025 – Regarding Short-Acting Beta 2 Agonists (SABA) (salbutamol and terbutaline) reminder of the risks from overuse in asthma and to be aware of changes in the SABA prescribing guidelines.

View Download
3
Cir.No.129 of 2025 – Regarding Short-Acting Beta 2 Agonists (SABA) (salbutamol and terbutaline) reminder of the risks from overuse in asthma and to be aware of changes in the SABA prescribing guidelines.
Was this page helpful?
0 visitors liked this page of total 0 visitors
Be the first to evaluate this page

Add Reason (choose at least one)

الرجاء اختيار سببان كحد أعلى

هذا الحقل مطلوب

الرجاء كتابة نص صحيح

الملاحظات يجب ان تكون اقل من ٢٥٠ حرف

Share this page
Follow Us On